SeNostic GmbH is a start-up company that was founded in 2022 after more than a decade of fundamental research and development in the field of molecular diagnostics for neurodegenerative diseases and that was sponsored by several national and private entities. After proof-of-concept has been shown and on the foundation of granted patents, a business model was established together with Ernst&Young. The company moved into the next stage to target final development for market entry. A modern facility with 600 m2 space for state-of-the art laboratories and offices is located in the Hannover Medical Park in Germany.
SeNostic GmbH has developed a medical device, „SeedCycler®“, its consumables (AmpliStripe®) and corresponding biochemical assays and data analytics to target biomarkers in different body fluids of human origin like CSF and blood in order to identify disease stages of neuro degenerations. The current portfolio comprises biomarkers for Parkinson, Alzheimer and Lewy-body-disease, like α-synuclein, Aβ, TDP43, and
The technology can be used as a key tool for pre-clinical drug screening and discovery, classification of patients for clinical studies and finally for early stage diagnostics in human patiens.
As a side product of the activities, the company offers biotechnologicaly produced recombinant proteins of the several biomarkers at high quality standards and competitive prices, that can be applied in other research and development all over the world or as standard reagents for diagnostics.